Synchrony Medical and Sheba Medical Center Initiate 1st Clinical Trial Using a Personalized Chest Physiotherapy System for Patients Living with Chronic Lung Diseases

Synchrony Medical* is a medical device company developing a personalized chest physiotherapy system designed to provide efficient airway clearance. They recently initiated a clinical trial at The National Cystic Fibrosis Center of Israel, at Sheba Medical Center**.

Synchrony Medical notes the trial aims to test the functionality of the system and compare its airway clearance effectiveness to the standard of care solutions currently used in Cystic Fibrosis and Bronchiectasis patients.

“Effective airway clearance on a daily basis at home is the key to keeping chronic lung patients stable and breaking the vicious cycle of clinical deteriorations,” said Dr. Moshe Ashkenazi, Pediatric Pulmonologist, Deputy Director, Safra Children’s Hospital, Sheba Medical Center, and Synchrony Medical’s Co-founder.

Synchrony Medical has developed a novel airway clearance system based on a unique chest physiotherapy method developed at the National Cystic Fibrosis Center of Israel, Sheba Medical Center. The system includes real-time sensing for an adaptive treatment to achieve effective airway clearance.

“Our system will enable patients to receive state-of-the-art chest physiotherapy independently, in the comfort of their own home,” explained Anat Shani, CEO of Synchrony Medical. “By making this effective therapy accessible, Synchrony Medical will bring to patient’s years of experience from Sheba’s respiratory experts and may help minimize pulmonary exacerbations and costly hospitalization associated with chronic lung diseases. This trial brings us one step closer to our goal: improving the lives of millions of chronic lung disease patients who deserve better airway clearance solutions.”

Synchrony Medical is a portfolio company of MEDX Xelerator, a medical device incubator formed as an initiative of MEDX Ventures Group together with Boston Scientific, Intellectual Ventures and Sheba Medical Center.

*Synchrony Medical, a portfolio company of MEDX Xelerator, is a clinical stage medical device company innovating airway clearance for patients living with chronic lung diseases. Synchrony’s system will enable patients to receive high quality chest physiotherapy independently at the comfort of their home.

The system synchronizes a unique chest compression sequence and the delivery of positive airway pressure with the patient’s breathing cycle, according to a personalized treatment algorithm. It is based on a unique airway clearance method developed at the National CF Center of Israel, at the Sheba Medical Center.

**The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer is generating global impact through its medical care, research and healthcare transformation. Sheba’s City of Health boasts an acute-care hospital, rehabilitation hospital, research and innovation hubs, medical simulation center and center for disaster response on one comprehensive campus in the center of Israel.

A university teaching hospital affiliated with the Sackler School of Medicine at Tel-Aviv University, Sheba is shaping the future of healthcare, educating the next generation of care providers. Sheba serves as a true hospital without borders, welcoming patients and healthcare professionals from all over the world and consistently providing the highest-level medical care to all in need. Sheba has been ranked a top-ten hospital in the world by Newsweek three years in a row (2019, 2020, 2021).

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”